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Introduction
Today, nearly 50 million people worldwide are living with de-
mentia (Prince et al., 2016). As one of the leading causes of 
age-related cognitive decline, Alzheimer’s disease (AD) rep-
resents a significant health concern for the aging population. The 
underlying cause remains incompletely determined, and to date 
no effective treatment has been discovered. Although remark-
able progress and scientific breakthroughs in recent decades 
have led to the development of effective protocols for diseases 
such as HIV and cancer, treatment therapies for neurodegen-
erative diseases such as Lewy body dementia and Alzheimer’s 
disease continue to lag significantly behind. Despite billions of 
dollars funneled into hundreds of clinical trials on various drug 
modalities, no truly effective etiological treatment or prophy-
lactic medication has been approved by the FDA to date. Of 
the five drugs that have been approved to treat the cognitive 
symptoms of Alzheimer’s disease, none have been shown to 
have more than a marginal or sustained effect on symptomatic 
patients with AD.
The Amyloid Hypothesis
AD onset is associated with a complex neurodegenerative cas-
cade mechanism histologically characterized by parenchymal 
deposition of amyloid-β (Aβ) and intracellular neurofibrillary 
tangle formation due to hyperphosphorylation of tau protein 
(Cunnane et al., 2011). Since the discovery of the Aβ peptide 
in 1984, the amyloid hypothesis has largely been the paradigm 
in understanding AD and the basis for researching potential 
therapeutic treatments. The amyloid hypothesis posits that 
the formation of senile plaques, composed predominantly of 
the proteinaceous Aβ peptide, leads to synaptic toxicity and 
cognitive deficits in AD (Banwait et al., 2008). In recent years, 
however, the  validity  of  this  theory has come into question; 
for although the neurotoxicity of Aβ is supported by substantial 
genetic and biochemical data,  Aβ-centered therapeutic trials 
aimed at limiting the production of  amyloid or facilitating its 
removal have failed to prove clinically effective in slowing cog-
nitive decline in AD patients (Pimplikar, 2009). These results 
suggest that perhaps, rather than being the primary cause of 
the disease, Aβ is a “downstream response to injury, with both 
beneficial and injurious properties” (McCaully & Grush 2017). 
With the entire premise of the current Alzheimer’s paradigm 
under question, it seems that perhaps a new understanding of 
the role of Aβ is necessary.
Paradigm Shift
Dr. Bredesen and associates address the inconsistencies of the 
prevalent amyloid cascade theory and clinical outcomes with 
a new approach, radically different than its monotherapeutic 
precedents. They have advanced a model in which, “AD results 
from an imbalance in endogenous plasticity signaling, and in 
which the β-amyloid precursor protein (APP) is a mediator of 
such plasticity-related signaling,” suggesting an etiology analo-
gous to chronic illness such as osteoporosis and arthroscle-
rosis. Osteoporosis occurs when there is a chronic imbalance 
between osteoblastic and osteoclastic signaling and new bone 
formation is exceeded by old bone resorption. “By analogy, in 
Alzheimer’s disease, there is a fundamental age-associated im-
balance between the dynamically opposed physiological pro-
cesses that mediate plasticity, i.e. between synaptoblastic and 
synaptoclastic activity” (Bredesen, 2014).  
Aβ is a peptide produced by the proteolytic cleavage of its pre-
cursor protein, APP, mediated by γ-secretase and β-secretase 
1 (Heneka et al., 2014). This integral membrane protein can 
be cleaved via two alternative pathways and in this way act as 
a molecular switch to mediate neuroplasticity. Amyloidogenic 
processing of APP leads to cleavage at the beta, gamma, and 
caspase sites to produce pro-AD peptides sAPPβ, Aβ, Jcasp, and 
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C31 - all of which have been shown to mediate neurite retrac-
tion and caspase activation. In contrast, the non-amyloidogenic 
processing of APP through cleavage at the alpha site results in 
the formation of sAPPα and αCTF, peptides which mediate neu-
rite extension and inhibit Aβ production and caspase activation 
(Bredesen, 2014; Chen, 2017).
In studies using regular and transgenic mice, both genetic 
and pharmacologic methods were used to manipulate the APP 
derivative peptide balance and were found to cause predict-
able effects on learning and memory. This suggests that the APP 
cleavage pathway may be a potential target to inhibit AD patho-
physiology. A number of agents that affect this pathway, including 
nitrin-1 and Aβ, have been identified, however, targeting any of 
these agents individually has had limited success. Additionally, 
other potential intervention targets, aside from Aβ oligomers, 
including inflammatory mediators, apolipoproteins, trophic fac-
tors and their receptors, and axoplasmic machinery have been 
identified. Although targeting any one of these pathways shows 
great promise in preclinical studies, it has not proven effective 
in human studies. This inconsistency seems to suggest that a 
“network-based therapeutics approach, rather than a single tar-
get-based approach, may be more effective for the treatment 
of cognitive decline due to Alzheimer’s disease” (Bredesen, 
2014). The complex, multifactorial nature of the disease may 
require interventions that target several risk factors and disease 
mechanisms simultaneously for optimum effect. Comprehensive 
combination therapies have been shown to greatly improve 
treatment of other chronic illnesses, such as HIV and cancer. 
In the case of HIV, the development of highly active antiretrovi-
ral therapy, a form of combination therapy, caused a significant 
decline in death rates for a disease that had been minimally 
treatable for decades (Brady et al., 2010).
The Finger Study
The Finnish Geriatric Intervention Study to Prevent Cognitive 
Impairment and Disability (FINGER) assessed a multi-domain 
approach towards improvement of cognitive functioning and 
prevention of cognitive decline in the first extensive, long-term, 
methodologically rigorous trial to date. They conducted a two-
year trial to confirm the associations of several modifiable fac-
tors, such as diet and physical inactivity, with Alzheimer’s disease.
Participants were required to be between 60-77 years of age 
and have a minimum CAIDE (Cardiovascular Risk Factors, Aging, 
and Dementia) Score of 6 points. The Consortium to Establish 
a Registry for Alzheimer’s disease Neuropsychological Battery 
Test was used for cognitive screening. Only participants who 
tested at or slightly lower than the mean level of cognitive per-
formance, as compared to the normal population, were included 
in the study. Individuals with diagnosed or suspected dementia, 
and several other disorders or impairments were excluded.
Participants were randomly assigned to the intensive 
multi-domain intervention or regular health advice group (control 
group) using computer-generated allocation at each of six testing 
centers. The trial was double-blinded to the maximum possible ex-
tent, wherein allocation was not disclosed to either participants or 
outcome assessors. Participants were restricted from interacting 
with each other and advised not to discuss their experiences.
Procedures
All participants met the study nurse five times during the two 
year trial where they received advice on a healthy diet, and phys-
ical, cognitive, and social activities to manage risk factors and 
prevent cognitive impairment. The intervention group received 
four additional components, including a nutritional intervention, 
a physical exercise training program, cognitive training, and so-
cial activities.
Results
There was significant improvement for the primary outcome 
in the intervention group, which showed 25% greater improve-
ment in the neuropsychological test battery (NTB) total score 
than the control group. The intervention group also showed 
higher improvements in executive function and processing 
speed than the control group, 83% and 150% respectively. There 
was no evidence, however, of significant change in memory for 
the intervention group (Ngandu et al., 2015).
A More Comprehensive Multi-Domain Approach 
to Treatment of Alzheimer’s Disease 
The ReCODE Protocol
The ReCODE Protocol outlines a more comprehensive thera-
peutic system that targets as many as 36 risk factors or disease 
mechanisms to prevent and reverse cognitive decline.  While 
the individual effects of any one of these factors may not be 
significant, the protocol targets many factors simultaneously to 
create a synergistic effect capable of reversing the imbalance 
of synoblastic/synoclastic activity mediated by APP. Typically, the 
evaluation of patients with cognitive decline does not include 
testing for genetics, inflammation, infection, homocysteine, fast-
ing insulin level, toxic exposure, blood brain barrier or body 
mass index, all of which are known risk factors for AD. Patients 
following the ReCODE Protocol undergo extensive lab and ge-
nome testing, referred to as a “cognoscopy,” to identify genetic 
risk factors and suboptimal physiological, metabolic, and cogni-
tive parameters. The results are used to generate a personalized 
ReCODE Report™ which designs an individualized protocol 
targeting the identified risk factors in order to synergistically 
achieve an optimum outcome (Bredesen, 2017).
Three Subtypes of Alzheimer’s
To optimize treatment development, Bredesen et al. uses 
metabolic profiling to distinguish between three subtypes of 
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Alzheimer’s disease, each with its own characteristic biomark-
ers. Although there may be overlap, each subtype requires re-
mediation of specific suboptimal indicators.
Subtype 1: Inflammatory
Carriers of the apolipoprotein E4 (ApoE4) gene are at in-
creased risk for developing AD, particularly the inflammatory 
subtype. Carriers homozygous for the ApoE4 allele often be-
come symptomatic as early as late forties or fifties, single ApoE4 
allele carriers in late fifties or sixties, while symptom onset for 
those without the gene is typically in the sixties to seventies. 
This subtype is associated with biomarkers of systemic inflam-
mation such as increased hs-CRP, IL-6 and TNFα as well as a 
decreased albumin:globulin ratio.  Symptomatically, this subtype 
is characterized by the loss of the ability to form new memories 
while retaining long-term memories and the ability to calculate, 
spell, and write. Brain atrophy of the hippocampus is evident 
early in the disease progression (Bredesen, 2017).
The Inflammation Hypothesis
Inflammation has been implicated in AD mechanisms and is 
believed to play a critical role in the pathogenesis of the dis-
ease. When Aloysius Alzheimer studied the post-mortem brain 
of Aguste Deter in 1907, he found microglia, the primary cells 
of the innate immune system involved in the brain inflamma-
tion response, clustered around the amyloid plaques. Initially, 
the inflammation hypothesis was regarded as unlikely or even 
impossible due to the view of the brain as an “immune-priv-
ileged organ,” allowing for inflammation only “through direct 
infection or after the breakdown of the blood brain barrier and 
subsequent infiltration of peripheral immune cells” (Heneka et 
al., 2014). However, extensive research over the last decade has 
confirmed the presence of neuroinflammation in AD and sug-
gests that its presence may even begin in preclinical stages of 
the disease (McCaully & Grush 2017). PET imaging has shown 
evidence of significantly increased levels of neuroinflammation 
markers in brain areas affected by AD neuropathology while 
almost no neuroinflammation was found in individuals with-
out dementia, despite high plaque burden (Krstic et al., 2012). 
Furthermore, several known risk factors for AD, such as a his-
tory of systemic infection, obesity, and reduced physical activity, 
are associated with some component of inflammation (Heneka 
et al., 2014). Increasing evidence suggests that neuroinflamma-
tion seems to correlate more directly with cognitive decline 
than plaque deposition alone.
Innate Immunity: Microglial Contribution to  
AD Pathogenesis
Innate immune cells, particularly microglia, have been implicat-
ed as mediators of neuroinflammation in AD and as contribu-
tors to its pathogenesis. Microglial cells are an essential part 
of the central nervous system and serve to protect the brain 
from injury and pathogenic invasion. In brain development, mi-
croglia assist in synapse formation and eliminate dysfunctional 
synaptic connections (Van Eldik et al., 2016). Rice, et. al. (cited 
in Spangenberg & Green, 2017) found that healthy adult mice, 
without a proliferation of microglia, showed 35% more syn-
apse-bearing dendritic spines than mice with significant microg-
lial proliferation, indicating that microglial participation in synap-
tic maintenance may continue even into adulthood through the 
dismantling of dendritic spines in the AD brain.
In the homeostatic adult brain microglia are in a “surveillance 
state,” constantly surveying the brain parenchyma to detect 
abnormalities and supporting neuronal health and function by 
regulating synaptic plasticity and pruning unnecessary synapses. 
Upon detection of an insult, such as Aβ plaques, these immune 
cells are activated and assume an entirely different phenotype 
with both chemical and morphological changes, including the 
retraction of their processes. This phenotypic change may inhib-
it the ability of microglia to alter and adapt synapses and con-
tribute to the impaired synaptic plasticity characterized by AD 
(Van Eldik et al., 2016). Once activated, microglia secrete pro-in-
flammatory cytokines, including TNFα, IL-6, and IL-1β to induce 
other cells to migrate to the injury site and mediate clearance 
of the invasive material through phagocytosis. In acute inflam-
matory events, the inflammatory response is resolved through 
regulatory proteins which induce microglia to secrete anti-in-
flammatory factors to promote tissue repair. The microglia then 
revert to their “surveillance state”. However, in AD, microglia 
are unable to phagocytose Aβ, as evidenced by the presence 
of plaques surrounded by microglial cells in post-mortem AD 
brains (Spangenberg & Green, 2017). This leads to the sustained 
release of pro-inflammatory mediators which “has been shown 
to be involved in the suppression of axonal transport and adult 
neurogenesis” (Heneka et al., 2014).
Inflammatory dyshomeostasis drives microglia into a state 
of chronic activation in which they no longer function prop-
erly, resulting in aberrant synaptic pruning, neuronal loss, and 
accumulation of Aβ, eventually leading to cognitive dysfunction 
(Spangenberg & Green, 2017). Cytokines, for instance, have been 
linked to cytoskeletal and synaptic alteration through increased 
tau phosphorylation and decreased synaptophysin levels. 
Experimental Correlation Between Innate Immune 
Activation and Neurodegenerative Disease
Numerous animal studies have linked immune responses to 
neurodegeneration. In one study, the NLRP3 gene, an important 
component of the neuroinflammatory pathway, was removed 
from APP/PS1 mice. This gene knockout resulted in reduced 
inflammation, enhanced Aβ clearance, as well as improved syn-
aptic plasticity and cognitive function (Heneka et al., 2013). In 
another experimental study, inflammation caused by systemic 
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immune challenges alone was revealed to trigger Alzheimer-like 
neuropathology in mice. Mice exposed to systemic immune 
stimulation prenatally and then again later in adulthood were 
predisposed to develop sporadic-like AD during aging. They 
displayed chronic microglial activation, increased Aβ deposition, 
and working memory impairment (Krstic et al., 2012). In another 
study, neutralizing increased levels of the inflammatory cytokine, 
IL-1β, was found to reduce Aβ and p-tau in triple-transgenic AD 
mice (Ferreira et al., 2014).
A recent study found a correlation between increased prolif-
eration of microglial cells in human AD and disease severity. To 
establish the influence of inflammation over the onset and pro-
gression of AD they targeted the colony-stimulating factor 1 re-
ceptor (CSF1R), a receptor protein that regulates the activation 
and proliferation of microglial cells. A tyrosine kinase inhibitor 
was administered to APP/PS1 to induce prolonged inhibition of 
CSF1R. This inhibition resulted in decreased microglial prolifera-
tion and improved performance in memory related tasks. These 
results support the “link of the inflammatory response gener-
ated by microglia...with the observed synaptic and behavioural 
deficits” (Olmos-Alonso, et. al. 2016).
In their review of innate immune activation in neurodegen-
erative disease, Heneka et al. conclude that neuroinflammation 
is likely not only a consequence but also an early cause of the 
pathology (Heneka et al., 2014).
Key Measures of Inflammation
C-reactive protein (CRP) is produced by the liver in response 
to inflammation. ReCODE protocol advises testing for hs-CRP 
(high sensitivity) as the standard CRP test cannot always distin-
guish optimal levels, below 0.9 mg/dl, from mildly abnormal lev-
els. The albumin to globulin ratio is a complementary measure 
of inflammation and should be at least 1.8. Fatty acids omega-6 
and omega-3 are pro and anti-inflammatory respectively.  Their 
ratio should be between 0.5 and 2.9. Levels of cytokines such 
as IL-6 and TNFα are also important indicators of inflammation. 
Concentration of IL-6 should be less than 3.0 pg/ml and that of 
TNFα should be less than 6.0 pg/ml. (Bredesen, 2017)
Reducing Inflammation
The ReCODE protocol recommends a three-pronged ap-
proach to reducing inflammation. Treating inflammation is of no 
use if the trigger is still present, so first, it is critical to remove 
the sources of inflammation by preventing exposure to “in-
flammagens”. There could be several sources, including chronic 
infection, viruses, a diet high in simple carbohydrates, leaky gut, 
and even poor oral hygiene. The second step is to resolve the 
inflammation through specialized pro-resolving mediator (SPM) 
supplements. SPMs are small cell signaling molecules such as 
resolvins, and maresins that have been identified during active 
inflammation resolution in the body and mediate the return 
to tissue homeostasis (Serhan et al., 2011). Chronic inflamma-
tion indicates the inability to return to homeostatic condition 
and SPM supplements can provide the missing resolution ag-
onists. The third step is to inhibit new inflammation through 
ingestion of anti-inflammatories such as omega-3 and curcumin 
(Bredesen, 2017).
Subtype 2: Non Inflammatory or Atrophic
Homozygous and heterozygous carriers of the ApoE4 allele are 
at increased risk for this subtype as well, though symptoms typ-
ically begin about a decade later than the inflammatory subtype. 
Symptoms are similar to those in inflammatory Alzheimer’s, with 
an impaired ability to form new memories but retained ability 
to write and calculate. Inflammation is not present and some of 
its biomarkers may actually be suboptimal. Rather, this subtype 
is associated with reduced overall support of synaptic plasticity 
marked by an atrophic profile, including insulin resistance, hypo-
vitaminosis D, hyperhomocysteinemia, and reductions in hor-
monal support from molecules such as estradiol, progesterone, 
and testosterone (Bredesen, 2017). While the extent to which 
each of these risk factors contributes to AD pathology is still 
being studied, scientists have proposed theoretical mechanisms 
to support the contribution of many of these mediators, includ-
ing homocysteine and insulin, to its pathogenesis.
Homocysteine
Epidemiological studies have associated increased levels of ho-
mocysteine (HC) with Alzheimer’s disease progression (Morris, 
2003). According to one study, homocysteine contributes to 
AD pathology through an Aβ-fibrinogen interaction. This in-
teraction induces the oligomerization of fibrin and the forma-
tion of abnormal fibrin clots which are resistant to fibrinolysis. 
Accumulation of fibrin clots leads to inflammation and disrup-
tion of the blood brain barrier. In their study, AD patients with 
high levels of homocysteine showed increased Aβ plaques and 
fibrinogen levels in the brains. Similarly, researchers induced hy-
perhomocysteinemia in an AD mouse model by administering a 
high methionine diet for several months. These mice displayed 
severe Aβ plaque deposition along with learning and memory 
impairments (Chung et al., 2016). Homocysteine is a marker of 
both inflammation and suboptimal nutritional support. Sufficient 
amounts of vitamins B6, B12, and B9 (folate) are required to 
maintain an optimal level, below 6 mM/L (Bredesen, 2017).
Insulin Resistance
Insulin resistance is another significant risk factor for AD. Insulin 
is degraded by a protein known as insulin degrading enzyme. 
This enzyme has also been linked to the decomposition of Aβ 
plaques. High levels of insulin require insulin degrading enzyme 
to be constantly breaking down excess insulin, thus limiting its 
opportunity to decompose Aβ plaques. High levels of glucose 
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also lead to the production of advanced glycation end prod-
ucts. These molecules trigger inflammation when they bind to 
their receptors, cause the formation of free radicals, and damage 
blood vessels, thus reducing nutritional support to the brain. 
Fasting insulin level should be 4.5 mIU/ml or below and fasting 
glucose level should be between 70-90 mg/dL (Bredesen, 2017).
Subtype 3: Cortical or Toxic
Subtype 3 is characterized by biomarkers of toxicity and typical-
ly occurs in carriers of the ApoE3 rather than the ApoE4 allele. 
Symptom onset is often earlier, in the late forties to early sixties, 
and following a period of great stress, sleep loss, anesthesia, or 
menopause. Cortical Alzheimer’s is completely different than 
the other two types; it is not predominantly amnestic in the 
early stages and presents itself instead with cortical deficits such 
as dyscalculia and aphasia. In addition to short-term memory 
loss, long-term memory loss, including procedural memory, is 
also affected (Bredesen, 2017). In these cases, PET imaging often 
indicates more general cerebral atrophy compared to the more 
restricted temporoparietal reduction typically seen in patients 
with subtypes 1 and 2 (Bredesen et al., 2016).
Current research seems to suggest a possible link between 
mercury toxicity and AD. In vitro studies have found that mer-
cury increases secretion of Aβ, causes structural changes in 
mitochondria which induce a response from the innate immune 
system. Mercury also interferes with membrane structures lead-
ing to the aggregation of neurofibrillary fibers and degeneration 
of neuronal axons (Walach et al., 2015). 
Exposure to other biotoxins such as arsenic has also been 
shown to affect neurological function. Arsenic exposure most 
commonly comes from groundwater, a phenomenon particular-
ly prevalent in western United States where certain areas are 
estimated to have over 300 times the permitted EPA level of 
arsenic in the drinking water. Gong et al. proposed the Arsenic 
Exposure Hypothesis for AD based on premises of existing hy-
potheses for the disease. They find correlations between arsenic 
toxicity and several typical pathological markers of the disease. 
These include the following: over transcription of APP, brain in-
flammatory response, and the generation of free radicals which 
cause oxidative stress and neuronal death (Gong et al., 2010).
Although much of the literature on arsenic toxicity details 
its cognitive effects on children, recent studies have correlated 
it with altered adult cognition as well. The FRONTIER Project 
is an ongoing study being conducted on residents living in West 
Texas, an area that contains significant levels of arsenic in the 
groundwater. Participants with long-term chronic exposure to 
arsenic scored lower on tests for global cognition, processing 
speeds and immediate memory (Tyler & Allan, 2014). 
It has been suggested that Toxic Alzheimer’s is a phenotyp-
ic manifestation of chronic inflammatory response syndrome 
(CIRS), commonly caused by exposure to biotoxins such as 
molds or tick-borne pathogens. Cognitive decline in both 
patients with CIRS and Type 3 Alzheimer’s is not limited to 
amnestic symptoms; it includes executive dysfunction often 
concomitant with hypozincemia, dysfunction of the hypothalam-
ic-pituitary-adrenal axis, and psychiatric effects such as depres-
sion. In the case studies of patients displaying type 3 symptoms, 
all of them had a history of significant toxic exposure (Bredesen, 
2016). Patients with the toxic subtype of Alzheimer’s also often 
present significantly high levels of copper and low levels of zinc 
which can cause increased sensitivity to toxins such as mercury 
and mold. A copper:zinc ratio of 1.4 or higher has been associ-
ated with dementia. 
ReCODE recommends treating metal toxicity in one of sev-
eral ways including chelation, or a gentler method called Detox 
Qube which helps optimize the natural detoxification process 
of the body to eliminate potentially toxic metals such as mer-
cury and arsenic. Treatment for toxicity from other toxins such 
as mold are more complicated and exposure specific and thus 
should be treated by a physician experienced in biotoxin-associ-
ated illness (Bredesen, 2017).
Additional Factors Addressed by ReCODE
The primary characteristic of the ReCODE protocol is its 
attempt to simultaneously address as many potential disease 
mechanisms as possible, including diet, exercise, and cognitive 
training, among others.
Ketogenic Diet: A Neuroprotective Mechanism
The protocol recommends that patients adhere to a ketogenic 
diet which has been associated with neuroprotective benefits. 
Ketogenic diets have been linked to several neuronal and syn-
apse supporting mechanisms. Studies have associated a ketogen-
ic diet with antioxidant effects, increased cerebral ATP indicating 
metabolic effects, and decreased expression of pro-apoptotic 
factors clusterin and caspase-3, implicating anti-apoptotic mech-
anisms as well. Additionally, it has been found that the presence 
of β-HB increases the synthesis of BDNF, a trophic factor which 
mediates neuroprotection and is associated with cognitive im-
provement (Bredesen, 2017). Growing evidence of brain glu-
cose hypometabolism in AD brains may provide a mechanism 
to explain this correlation; namely that the abundance of ketone 
bodies (KB) made available by a ketogenic diet may compensate 
for the decreased glucose uptake in the brain by acting as a fuel 
replacement, allowing the brain to work more efficiently.
Ketone Bodies and Brain Glucose Hypometabolism
The adult brain uses close to 23% of the body’s total energy 
requirement, despite representing only about 2% of total body 
weight, with glucose used as the predominant form of fuel. It is 
well documented that glucose metabolism is significantly deterio-
rated in patients with AD. PET imaging has even shown significant 
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hypometabolism in subjects with risk factors for AD prior to the 
manifestation of any symptoms of cognitive decline. A recent re-
view of several independent studies conducted on various groups 
at risk for AD shows evidence of increased presymptomatic brain 
glucose hypometabolism, ranging from 12-20% as compared to 
the control, in all at-risk groups (Cunnane et al., 2016). 
For instance, subjects who were homozygous for the E4 al-
lele with a family history of AD, both risk factors for developing 
AD, were screened for glucose hypometabolism against a control 
group. Despite no difference in cognitive test results, the exper-
imental group displayed decreased glucose metabolism in the 
same brain regions identified in AD subjects, specifically in the 
posterior cingulate and prefrontal, parietal, and temporal cortices 
(Reiman et al., 2004). This indicates the possibility that PET scans 
measuring the cerebral metabolic rate of glucose (CMRg) can 
even be used to predict the onset of the disease.
Given the necessity of the brain for a constant energy supply, 
Cunnane et al. has proposed that glucose hypometabolism in the 
brain causes chronic, gradual brain energy starvation and may be 
part of the disease etiology of AD. Thus, it seems reasonable for 
potential therapeutic strategies to be aimed at correcting the 
underlying problem of deteriorating brain fuel supply, specifically 
by studying the body’s normal method of coping with decreased 
glucose availability which occurs during fasting, malnutrition, or 
strenuous exercise. When glucose supply is severely compro-
mised, the brain uses ketone bodies, specifically β-hydroxybutyr-
ate and acetoacetate, as the main reserve fuel (Owen et al., 1967). 
Ketone vs Glucose Metabolism and Uptake
A study comparing brain glucose and ketone uptake was con-
ducted to determine whether hypometabolism in the brain is 
generalized to include both glucose and ketone metabolism or 
a condition specific to glucose. Results showed that global brain 
FDG (glucose analogue used in PET imaging) uptake was 14% 
lower in early AD patients than the control group while no sig-
nificant difference in C-Ac (acetoacetate analogue) uptake was 
found. Thus, it seems possible that providing more KB to offset 
the deficit in energy caused by glucose hypometabolism in aging 
brains may decrease neuronal shrinkage and lower the risk of 
developing AD. Indeed, clinical studies suggest that nutritional 
treatments to increase plasma KB concentration may be effec-
tive against cognitive decline in early stages of AD (Cunnane et 
al., 2016).
This theory has been tested in a cell culture model of AD with 
positive results. Hippocampal cells of embryonic rats exposed 
to Aβ42 demonstrated a 50% decrease in cell number. When 
these cells were simultaneously exposed to β-HB, cell survival 
doubled, indicating the potentially protective nature of β-HB 
from amyloid toxicity (Henderson, 2008). The effectiveness of 
ketone body treatment in human AD subjects has also been 
tested in clinical trial. In this study, subjects with mild to mod-
erate probable AD consumed a beverage containing emulsified 
medium-chain triglycerides (MCTs) to induce elevated serum 
KB levels. Due to its shorter chain length, MCTs generate the 
rapid production of ketone bodies, unlike longer fatty acid 
chains. After 90 minutes, neurophyscological testing showed 
a significant correlation between increased serum β-HB con-
centration and memory improvement, specifically for subjects 
without the ApoE4 allele (Reger et. al, 2004).
The Ketoflex 12/3 Diet
Due to significant evidence indicating the positive effects of a 
ketogenic state on cognitive function, the ReCODE Protocol 
posits the need for a ketogenic nutritional plan, referred to as 
the “Ketoflex 12/3” diet. The typical western diet is high in car-
bohydrates which inhibit ketogenesis and the utilization of KB. 
A ketogenic diet promotes the release of free fatty acids to be 
synthesized into KB, a process which is normally inhibited by 
insulin signaling in the presence of carbohydrates.
The Keto in Ketoflex 12/3 refers to the induced state of 
ketosis through a high-fat, low carbohydrate, plant-based diet. 
Consumption of MCTs has also been shown to help induce 
mild-ketosis and is recommended as well. These include coco-
nut oil and palm kernel oil, of which approximately 10% consist 
of these medium chain fatty acids, or MCT oil which is a con-
centrated form of the fraction of medium chain fatty acids in 
coconut oil (Cunnane et al., 2016).
The flex in the Ketoflex 12/3 diet reflects the flexibility and 
variety of food choices. The diet is mainly plant-based with 
consumption of protein limited to just a few ounces a day. The 
consumption of too much protein causes some of it to be con-
verted to carbohydrates. In his book, The End of Alzheimer’s, Dr. 
Bredesen outlines some specifics regarding food choices. These 
include the following: choosing mainly foods with a glycemic 
index lower than 35, as these foods do not require significant in-
sulin release; eating detoxifying plants such as cilantro, crucifer-
ous vegetables, kale, maca, and avocados to help eliminate toxins 
such as heavy metals and Bisphenol A; and getting probiotics 
and prebiotics either in pill form or from fermented foods such 
as kimchi and sauerkraut, to help optimize bacteria in the gut. 
He also recommends reducing cooking times and temperatures 
to reduce the production of advanced glycation end products 
which create inflammation, and optimizing nutrition with sup-
plements such as reservatol, nicotinamide riboside, citricoline, 
ubiquinol and polyquinoline quinine (Bredesen, 2017).
The 12/3 refers to the fasting times; namely a 12 hour fasting 
period between the last meal at night and the first meal of the 
next morning, and a 3 hour minimum between dinner and bed-
time. As previously discussed, fasting is a highly effective way to 
induce ketosis.
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Stress Management
There are several mechanisms that may account for the associ-
ation of chronic unresolved stress with cognitive decline. Stress 
activates the HPA axis to stimulate the release of stress related 
hormones, such as cortisol, from the adrenal glands. Increased 
levels of cortisol can lead to neuronal damage, particularly in 
the hippocampus, thus contributing to cognitive and memory 
decline.  Stress also increases several risk factors for AD includ-
ing blood glucose levels and hyperstimulation of neurons. Stress 
is most closely linked with Type 3 Alzheimer’s, where onset of 
cognitive decline often coincides with a stressor. Therefore, a 
program for stress reduction is included in the ReCODE pro-
tocol, including meditation and yoga to lower cortisol levels and 
prevent hippocampal atrophy (Bredesen, 2017)
Sleep Optimization
There are several neural mechanisms through which sleep af-
fects cognition. Sleep is associated with reduced amyloid plaque 
formation and induces autophagy in the brain, recycling dysfunc-
tional components and improving cellular health. Production of 
growth hormone increases during sleep allowing for cell repair 
and production of supportive brain cells. More hours of sleep 
allow for a longer period of fasting which helps improve insulin 
sensitivity. ReCODE recommends at least 8 hours of sleep and 
the use of melatonin if falling asleep is difficult (Bredesen, 2017).
Physical Activity
Exercise has been linked to many benefits related to cognition. 
Among them are: reduced insulin resistance, increased ketosis, 
stress reduction, improved sleep, and increased size of the hip-
pocampus which is a key region in memory and shows atrophy 
in AD. For optimal cognition benefits, ReCODE recommends 
combining aerobic exercise with weight training 5 days a week 
for 45 - 60 minutes per day (Bredesen, 2017).
Cognitive Training
Although the effects of brain exercises are controversial, cog-
nitive training was one of the additional intervention elements 
given to the intervention group of the FINGER study which 
suggest a positive correlation between brain exercises and cog-
nition (Ngandu et al., 2015). 
Patient Case Studies 
The results of the multi-domain therapeutic system utilized by 
Bredesen et al. on 10 patients is summarized in the table below. 
As indicated, patients either reverted to their normal mental 
status prior to exhibiting symptoms of cognitive impairment, or 
showed improvement in cognition. One patient with advanced 
AD, however, showed decline. These results suggest that mem-
ory loss in cases of Subjective Cognitive Impairment (SCI), Mild 
Cognitive Impairment (MCI), and early AD may be reversed and 
show sustained improvement using the therapeutic program 
described by the ReCODE protocol (Bredesen, 2017).
Conclusion
Although preliminary results of this study seem promising, un-
like the FINGER study, the results are only anecdotal and fail 
to include predefined criteria for success, any indication as to 
how patients were selected for inclusion, or clear descriptions 
of the exact protocol followed for each patient. Additionally, the 
protocol addresses many biomarkers that have been implicated 
in AD without proving whether they are etiologically or epiphe-
nomenally linked. There is also no control group for comparison. 
Thus a more extensive, controlled clinical trial is required to de-
termine the broad range effectiveness of the ReCODE protocol 
on cognitive impairment.
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